PHION TECHNOLOGY
PHION TECHNOLOGY
HOW DOES RALA WORK?
RALA can rapidly condense all nucleic acids (irrespective of size) and other anionic small molecules (such as chemotherapies, cyclic dinucleotides, nucleotides etc.) to form stable nanoparticles that readily cross cell membranes, escape endosomes to release the cargo with high transfection efficiency and low associated toxicity.
RALA Peptide : POSITIVE CHARGES
Drug Cargo : NEGATIVE CHARGES
(e.g. DNA, RNA, or Small Molecules)
SELF-ASSEMBLY OF ION PAIRS
Z-Average
< 100 nm
Forms Consistent & Stable Nanoparticles
Regardless of Cargo Type or Size
BENEFITS OF RALA
SCALABLE
Can condense multiple nucleic acids or anionic small molecules into nanoparticles with industry acceptable characteristics at a clinical relevant scale
EFFICIENT
Cellular delivery of nucleic acids that outperforms current delivery platforms in vitro. RALA nanoparticles are capable of entering cells, disrupting endosomes, and releasing the cargo for maximal effect
RESISTANT
Physiologically stable nanoparticles with no protein binding, nanoparticle disassembly, or nanoparticle aggregation following exposure to physiological concentrations
SAFE
The natural amino acid composition ensures no toxicity even after multiple transfections in vitro or injections in vivo
THERAPEUTIC
RALA nanoparticles exhibit low immunogenicity. No vector neutralization or anti‐RALA antibodies are detected following repeated exposure in immune competent mice
STABLE
Highly stable formulations (>18 months) that are resistant to extremes of time and temperature, remaining intact and functional with no loss in transfection efficiency following lyophilisation
Mechanism Of Action
Ionic interactions between peptide and cargo allow nanoparticles to self-assemble with drug cargo making formulation simple, easy, and repeatable.
Positive (cationic) peptide with Negative (anionic) cargo
The ionic bond being formed with the cargo is typically both bidentate and bifurcated (two ionic interactions at a site with two or more sites forming bond). This leads to extremely strong bonding and unsurpassed stability of RALA nanoparticles.
The net cationic nanoparticles now possess the ideal physiochemical characteristics and are readily taken up by cells, crossing the cell membrane with ease and being taken into cellular compartments known as endosomes.
The reduction in pH inside the endosome triggers a conformational change in the RALA peptide, enabling fusion with the endosomal membrane and subsequent proteolytic cleavage to release the cargo at the intended site of action.